After Chemotherapy in Childhood, Cancer 20 times More Likely to Recur

[Guest guest]

http://www.news-medical.net/?id=23993

Translocation kidney cancer after chemotherapy in childhood

This article out of Johns Hopkins reviewed the risk of renal cell carcinoma

occurring as a secondary malignancy after chemotherapy in childhood.

It is known that children who survive cancer are at the risk of developing

another malignancy 20 times more likely than the general population. This

study described the clinical, pathologic, cytogenetic, and molecular data on

six translocation renal cell carcinomas that arose in five patients who had

received chemotherapy.

At the time of diagnosis, the children were between the ages of 6-22 years.

Histologically, the tumor showed typical features that are described for

translocation renal cell carcinomas. At the molecular level, three of the

tumors contained the ASPL-TFE3 fusion; two contained Alpha-TFEB and one

contained PRCC-TFE3. The time span between chemotherapy and the diagnosis of

these renal cell carcinomas ranged from 4-13 years. The indications varied

and including acute promyelocytic leukemia, acute myeloid leukemia,

bilateral Wilms' tumor, systemic lupus erythematosus, and a conditioning

regimen of bone marrow transplantation secondary to Hurler's syndrome. This

latter patient also received radiation.

The group had 39 genetically confirmed translocation renal cell carcinomas

in their experience with six (15%) of these arising in patients who received

cytotoxic chemotherapy. They make the conclusion that cytotoxic chemotherapy

may predispose patients to the development of renal translocation

carcinomas.

Argani P, Lae M, Ballard ET, Amin M, Manivel C, Hutchinson B, Reuter VE,

Ladanyi M.

Urological Oncology: Seminars and Original Investigation 24 (6): 558-559,

December 2006.

By Pasquale Casale, MD

http://www.urotoday.com .

 

 

 

 

 

 

 

 

 

 

 

Ahhh...imagining that irresistible " new car " smell?

Check outnew cars at Autos.

 

 

[Guest guest]

When one notices that the side effect of chemo is immune function impairment it

all makes sense.

Chemo should be abandoned as a barbaric practice.

Allopathic medicine is the fine art of subacute poisoning. A lot of pharma

products have a narrow range between medicinal and lethal doseage.

 

Kirk

 

Courtney Kinear <ckinear wrote:

 

 

 

http://www.news-medical.net/?id=23993

Translocation kidney cancer after chemotherapy in childhood

This article out of Johns Hopkins reviewed the risk of renal cell carcinoma

occurring as a secondary malignancy after chemotherapy in childhood.

It is known that children who survive cancer are at the risk of developing

another malignancy 20 times more likely than the general population. This

study described the clinical, pathologic, cytogenetic, and molecular data on

six translocation renal cell carcinomas that arose in five patients who had

received chemotherapy.

At the time of diagnosis, the children were between the ages of 6-22 years.

Histologically, the tumor showed typical features that are described for

translocation renal cell carcinomas. At the molecular level, three of the

tumors contained the ASPL-TFE3 fusion; two contained Alpha-TFEB and one

contained PRCC-TFE3. The time span between chemotherapy and the diagnosis of

these renal cell carcinomas ranged from 4-13 years. The indications varied

and including acute promyelocytic leukemia, acute myeloid leukemia,

bilateral Wilms' tumor, systemic lupus erythematosus, and a conditioning

regimen of bone marrow transplantation secondary to Hurler's syndrome. This

latter patient also received radiation.

The group had 39 genetically confirmed translocation renal cell carcinomas

in their experience with six (15%) of these arising in patients who received

cytotoxic chemotherapy. They make the conclusion that cytotoxic chemotherapy

may predispose patients to the development of renal translocation

carcinomas.

Argani P, Lae M, Ballard ET, Amin M, Manivel C, Hutchinson B, Reuter VE,

Ladanyi M.

Urological Oncology: Seminars and Original Investigation 24 (6): 558-559,

December 2006.

By Pasquale Casale, MD

http://www.urotoday.com .